Rhumbline Advisers Has $2.03 Million Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Rhumbline Advisers grew its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 3.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,385 shares of the company’s stock after buying an additional 1,665 shares during the period. Rhumbline Advisers owned approximately 0.12% of Apogee Therapeutics worth $2,032,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in APGE. Driehaus Capital Management LLC boosted its stake in Apogee Therapeutics by 2.8% during the 4th quarter. Driehaus Capital Management LLC now owns 2,605,310 shares of the company’s stock valued at $118,021,000 after purchasing an additional 71,703 shares during the period. Alliancebernstein L.P. boosted its position in shares of Apogee Therapeutics by 13.5% in the fourth quarter. Alliancebernstein L.P. now owns 1,355,185 shares of the company’s stock valued at $61,390,000 after acquiring an additional 160,822 shares during the period. Paradigm Biocapital Advisors LP boosted its position in shares of Apogee Therapeutics by 82.9% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,283,766 shares of the company’s stock valued at $58,155,000 after acquiring an additional 581,949 shares during the period. Janus Henderson Group PLC grew its stake in shares of Apogee Therapeutics by 141.7% in the fourth quarter. Janus Henderson Group PLC now owns 1,135,100 shares of the company’s stock worth $51,455,000 after acquiring an additional 665,543 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Apogee Therapeutics by 38.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,052,595 shares of the company’s stock worth $47,683,000 after acquiring an additional 294,514 shares during the period. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Price Performance

Shares of NASDAQ APGE opened at $42.61 on Tuesday. Apogee Therapeutics, Inc. has a one year low of $26.20 and a one year high of $63.50. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of -17.61 and a beta of 1.38. The stock’s fifty day moving average price is $37.56 and its two-hundred day moving average price is $39.39.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.19) by $0.24. On average, equities analysts anticipate that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Insider Activity at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 3,860 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $36.22, for a total value of $139,809.20. Following the completion of the sale, the insider now owns 247,173 shares in the company, valued at $8,952,606.06. This represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 9,310 shares of company stock worth $337,944 in the last 90 days. Corporate insiders own 42.77% of the company’s stock.

Wall Street Analysts Forecast Growth

APGE has been the topic of a number of recent research reports. Wedbush reissued an “outperform” rating and set a $90.00 target price on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Citigroup assumed coverage on Apogee Therapeutics in a research report on Thursday, March 13th. They issued a “buy” rating and a $95.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Apogee Therapeutics presently has an average rating of “Buy” and an average price target of $94.60.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.